semaglutide bimagrumab + plus alone or in combination for the treatment of obesity: a randomized phase 2 trial Next-Generation Myostatin Inhibitors: Bimagrumab, Trevogrumab, – Weight loss and muscle loss.

Heart Health A healthy heart is a strong heart

Key Questions Answered in the GLP-1 Agonists - Pipeline Insight Report Which companies/institutions are leading the GLP-1 agonists drug development

If you want a needle-free, evidence-backed path to weight loss, the actionable starting point is a physician-supervised GLP-1 program

[DOI] [PMC free article] [PubMed] [Google Scholar] 109.Viallard C., Larrive B

MENLO PARK, Calif., May 7, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, in partnership with Mayo Clinic researchers, presented new findings at Digestive Disease Week (DDW) 2025 showing its proprietary machine-learning algorithms can predict which patients are more likely to experience side effects, specifically nausea, from GLP-1 therapies

Doctors look for this black color to check for bleeding in the stomach or intestines